Hyaluronic Acid Filler IMD1 Basic for Correction of Nasolabial Folds


Volunteers receive one injection IMD1 basic of correction of nasolabial folds and are followed-up for up to 36 weeks.

Full Title of Study: “Prospective, Multicentre, Not Controlled Clinical Study to Investigate Efficacy and Tolerability of the Hyaluronic Acid Filler IMD1 Basic After Single Bilateral Injection for Correction of Nasolabial Folds (NLF)”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)


  • Drug: Hyaluronic acid filler/IMD1 basic

Clinical Trial Outcome Measures

Primary Measures

  • Severity rating scale assessed by independent rater

Participating in This Clinical Trial

Inclusion Criteria

  • main inclusion criteria:

severity rating scale grade 3 or 4 Exclusion Criteria:

  • main exclusion criterion: other nasolabial fold corrections within 6 months prior to study entry

Gender Eligibility: All

Minimum Age: 30 Years

Maximum Age: 60 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Merz Pharmaceuticals GmbH
  • Overall Official(s)
    • Johannes Reinm├╝ller, MD, Principal Investigator, Klinik am Sonnenberg, Wiesbaden, Germany

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.